5-cyclopentyl-2-((5-(4-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentyl)-1H-1,2,3-triazol-4-yl)piperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethyl-5H-pyrrolo[3,2-d]pyrimidine-7-carboxamide

ID: ALA5273652

Max Phase: Preclinical

Molecular Formula: C43H50N14O5

Molecular Weight: 842.97

Names and Identifiers

Canonical SMILES:  CN(C)C(=O)c1cn(C2CCCC2)c2cnc(Nc3ccc(N4CCN(c5cn(CCCCCNc6cccc7c6C(=O)N(C6CCC(=O)NC6=O)C7=O)nn5)CC4)cn3)nc12

Standard InChI:  InChI=1S/C43H50N14O5/c1-52(2)40(60)30-25-56(27-9-4-5-10-27)33-24-46-43(49-38(30)33)47-34-15-13-28(23-45-34)53-19-21-54(22-20-53)35-26-55(51-50-35)18-7-3-6-17-44-31-12-8-11-29-37(31)42(62)57(41(29)61)32-14-16-36(58)48-39(32)59/h8,11-13,15,23-27,32,44H,3-7,9-10,14,16-22H2,1-2H3,(H,48,58,59)(H,45,46,47,49)

Standard InChI Key:  FCURMICREJRIDK-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 62 70  0  0  0  0  0  0  0  0999 V2000
    0.1681   -2.8197    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8825   -2.4072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9687   -1.5872    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7752   -1.4156    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1875   -2.1298    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6357   -2.7426    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0124   -2.1298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4250   -1.4154    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2499   -1.4154    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6623   -0.7010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4873   -0.7010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8997    0.0133    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.7247    0.0133    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9599    0.7270    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1374    0.7277    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3724    0.0123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9634   -0.6993    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1389   -0.7040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8840    1.5101    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5499    1.9928    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.2148    1.5088    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5499    2.8178    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8355    3.2303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8355    4.0552    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.5499    4.4677    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2644    4.0552    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2644    3.2303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0871    1.7236    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.0116    1.7223    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.5499    5.2926    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.1211    2.8178    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.1681   -3.6447    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5462   -4.0571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2606   -3.6446    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2606   -2.8196    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5462   -2.4072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9750   -4.0571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9753   -4.8821    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6880   -5.2926    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4026   -4.8801    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4042   -4.0592    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6926   -3.6428    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1170   -5.2925    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8315   -4.8801    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5460   -5.2923    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2579   -4.8804    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2579   -4.0553    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5477   -3.6435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8315   -4.0516    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8745   -3.4881    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5469   -2.7568    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7270   -2.8470    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1436   -2.2637    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3572   -1.4669    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7737   -0.8835    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1539   -1.2533    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3468   -2.4772    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6713   -3.7016    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8848   -4.4984    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7261   -4.5319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.0116   -3.7789    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3637   -3.2616    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  3  2  1  0
  3  4  2  0
  4  5  1  0
  5  6  1  0
  6  2  2  0
  5  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 14 15  1  0
 15 13  2  0
 16 14  2  0
 17 16  1  0
 18 17  2  0
 13 18  1  0
 15 19  1  0
 19 20  1  0
 20 21  1  0
 14 21  1  0
 22 20  1  0
 22 23  1  0
 24 23  1  0
 25 24  1  0
 26 25  1  0
 22 27  1  0
 27 26  1  0
 19 28  2  0
 21 29  2  0
 25 30  2  0
 23 31  2  0
 32  1  1  0
 33 32  1  0
 34 33  1  0
 35 34  1  0
 36 35  1  0
  1 36  1  0
 37 34  1  0
 38 37  2  0
 39 38  1  0
 40 39  2  0
 41 40  1  0
 37 42  1  0
 42 41  2  0
 40 43  1  0
 43 44  1  0
 45 44  2  0
 46 45  1  0
 47 46  2  0
 48 47  1  0
 49 48  2  0
 44 49  1  0
 47 50  1  0
 50 51  1  0
 52 51  2  0
 48 52  1  0
 52 53  1  0
 53 54  1  0
 54 55  1  0
 54 56  1  0
 53 57  2  0
 58 50  1  0
 58 59  1  0
 59 60  1  0
 60 61  1  0
 58 62  1  0
 62 61  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5273652

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 842.97

Molecular Weight (Monoisotopic): 842.4089

AlogP: 3.99

#Rotatable Bonds: 14

Polar Surface Area: 208.71

Molecular Species: NEUTRAL

HBA: 16

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 19

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 11.56

CX Basic pKa: 3.93

CX LogP: 4.38

CX LogD: 4.38

Aromatic Rings: 5

Heavy Atoms: 62

QED Weighted: 0.11

Np Likeness Score: -1.22

References

1. Li D, Yu D, Li Y, Yang R..  (2022)  A bibliometric analysis of PROTAC from 2001 to 2021.,  244  [PMID:36274273] [10.1016/j.ejmech.2022.114838]

2. Gray, N S NS and 12 more authors.  1998-07-24  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.  [PMID:9677190]

3. Kubo, A A and 9 more authors.  1999-12  The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.  [PMID:10632371]

4. Soni, R R and 7 more authors.  2000-09-07  Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product.  [PMID:10973815]

5. Lane, M E ME and 9 more authors.  2001-08-15  A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.  [PMID:11507069]

6. Tavares, Francis X FX and 7 more authors.  2004-09-09  N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.  [PMID:15341487]

7. Fry, David W DW and 10 more authors.  2004-11  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.  [PMID:15542782]

8. Pennati, Marzia M and 12 more authors.  2005-09  Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.  [PMID:16170024]

9. Sridhar, Jayalakshmi J, Akula, Nagaraju N and Pattabiraman, Nagarajan N.  2006-03-24  Selectivity and potency of cyclin-dependent kinase inhibitors.  [PMID:16584130]

10. DePinto, Wanda W and 19 more authors.  2006-11  In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.  [PMID:17121911]

11. Joshi, Kalpana S KS and 7 more authors.  2007-03  In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.  [PMID:17363486]

12. Squires, Matthew S MS and 7 more authors.  2009-02  Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.  [PMID:19174555]

13. Cirstea, D D and 15 more authors.  2013-12  Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.  [PMID:23807770]

14. Gelbert, Lawrence M LM and 16 more authors.  2014-10  Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.  [PMID:24919854]

15. Paiva, Cody C and 8 more authors.  2015  Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.  [PMID:26606677]

16. Bisi, John E JE, Sorrentino, Jessica A JA, Roberts, Patrick J PJ, Tavares, Francis X FX and Strum, Jay C JC.  2016-05  Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.  [PMID:26826116]

17. Klaeger, Susan S and 47 more authors.  2017-12-01  The target landscape of clinical kinase drugs.  [PMID:29191878]

18. Wang, Yan Y and 10 more authors.  2018-03-01  Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.  [PMID:29429832]

19. Tear, Westley F and 16 more authors.  2020-01-23  Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis.  [PMID:31846577]

20. Wu, Tizhi and 6 more authors.  2020-11-25  Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.  [PMID:32866383]

Source

Source(1):

• Scientific Literature